Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
FDA Approves Bimekizumab for Hidradenitis Suppurativa
The US Food and Drug Administration has approved bimekizumab, a humanized interleukin (IL)-17A and IL-17F antagonist, for the treatment of adults with moderate to severe hidradenitis suppurativa (HS). Approval was based on results from two phase 3 studies, BE HEARD…
English